Walleye Capital LLC Invests $1.64 Million in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Walleye Capital LLC acquired a new position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPNGet Rating) during the first quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 50,638 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,637,000. Walleye Capital LLC owned 0.09% of Supernus Pharmaceuticals at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. C M Bidwell & Associates Ltd. acquired a new stake in shares of Supernus Pharmaceuticals during the 4th quarter worth approximately $43,000. Captrust Financial Advisors lifted its holdings in Supernus Pharmaceuticals by 163.3% in the 1st quarter. Captrust Financial Advisors now owns 2,983 shares of the specialty pharmaceutical company’s stock valued at $96,000 after purchasing an additional 1,850 shares in the last quarter. Eqis Capital Management Inc. purchased a new position in Supernus Pharmaceuticals in the 1st quarter valued at $200,000. Hancock Whitney Corp purchased a new position in Supernus Pharmaceuticals in the 1st quarter valued at $201,000. Finally, Euclidean Technologies Management LLC purchased a new position in Supernus Pharmaceuticals in the 1st quarter valued at $208,000. Institutional investors and hedge funds own 99.81% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on SUPN shares. StockNews.com upgraded Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, September 2nd. Piper Sandler raised their price objective on Supernus Pharmaceuticals to $38.00 in a report on Tuesday, September 6th.

Supernus Pharmaceuticals Stock Up 0.2 %

NASDAQ SUPN opened at $34.90 on Friday. Supernus Pharmaceuticals, Inc. has a 52 week low of $24.95 and a 52 week high of $36.08. The business’s fifty day simple moving average is $32.64 and its 200-day simple moving average is $30.49. The firm has a market cap of $1.87 billion, a PE ratio of 34.55 and a beta of 1.01.

Supernus Pharmaceuticals (NASDAQ:SUPNGet Rating) last posted its quarterly earnings results on Thursday, August 4th. The specialty pharmaceutical company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.15). Supernus Pharmaceuticals had a return on equity of 6.98% and a net margin of 9.12%. The company had revenue of $170.10 million for the quarter, compared to analysts’ expectations of $164.23 million. During the same quarter in the prior year, the firm earned $0.43 EPS. The firm’s revenue was up 20.4% on a year-over-year basis. Research analysts expect that Supernus Pharmaceuticals, Inc. will post 1.51 EPS for the current year.

Insider Transactions at Supernus Pharmaceuticals

In related news, VP Tami Tillotson Martin sold 5,000 shares of the firm’s stock in a transaction dated Monday, August 22nd. The stock was sold at an average price of $35.98, for a total transaction of $179,900.00. Following the completion of the sale, the vice president now directly owns 87,220 shares of the company’s stock, valued at approximately $3,138,175.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, VP Tami Tillotson Martin sold 5,000 shares of the firm’s stock in a transaction dated Monday, August 22nd. The stock was sold at an average price of $35.98, for a total transaction of $179,900.00. Following the completion of the sale, the vice president now directly owns 87,220 shares of the company’s stock, valued at approximately $3,138,175.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Jack A. Khattar sold 39,431 shares of the firm’s stock in a transaction dated Tuesday, August 9th. The stock was sold at an average price of $31.15, for a total value of $1,228,275.65. Following the sale, the chief executive officer now directly owns 724,978 shares of the company’s stock, valued at $22,583,064.70. The disclosure for this sale can be found here. Insiders have sold a total of 66,733 shares of company stock worth $2,161,863 in the last quarter. Company insiders own 7.99% of the company’s stock.

About Supernus Pharmaceuticals

(Get Rating)

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age.

Further Reading

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.